THE ROLE OF INTERFERON-GAMMA IN THE TREATMENT OF VISCERAL AND DIFFUSE CUTANEOUS LEISHMANIASIS
THE ROLE OF INTERFERON-GAMMA IN THE TREATMENT OF VISCERAL AND DIFFUSE CUTANEOUS LEISHMANIASIS
复制标题
DOI：
10.1093/infdis/167.supplement_1.s13
复制
发表时间：
1993-03-01
影响因子：
6.4
通讯作者：
JOHNSON, WD
中科院分区：
文献类型：
--
作者：
BADARO, R;JOHNSON, WD
传统上，内脏和弥漫性皮肤利什曼病治疗的主要药物是五价锑，而喷他脒和阿替霉素B仅用于难治性病例。干扰素-γ（IFN-γ）联合五价锑已成功用于治疗五价锑难治性患者和既往未经治疗的内脏利什曼病患者（共39例）。此外，6例弥漫性皮肤利什曼病患者接受了IFN-γ和锑联合治疗。这些患者的初步经验表明，IFN-γ是一种有用的辅助治疗严重或难治性内脏利什曼病的情况下，然而，IFN-γ治疗弥漫性皮肤利什曼病的潜力，不能评估目前的临床经验是太有限。
Traditionally, the mainstay of visceral and diffuse cutaneous leishmaniasis therapy has been pentavalent antimony, with pentamidine and amphotericin B reserved for refractory cases. Interferon-gamma (IFN-gamma) in combination with pentavalent antimony has been used successfully in treating patients refractory to pentavalent antimony and in patients with previously untreated visceral leishmaniasis (39 total). In addition, 6 patients with diffuse cutaneous leishmaniasis have been treated with combination IFN-gamma and antimony therapy. Preliminary experience with these patients indicates that IFN-gamma is a useful adjunct therapy for severe or refractory cases of visceral leishmaniasis; however, the potential of IFN-gamma in treating diffuse cutaneous leishmaniasis cannot be assessed as current clinical experience is too limited.